Inflammatory reactions in the skin can reduce damage from UV radiation or infections, but can also result in painful symptoms such as sunburn. A recent study at the University of Bonn and the University Hospital Bonn has ...
Nov 2, 2022
0
4
A vaccine for eastern equine encephalitis virus (EEEV), western equine encephalitis virus (WEEV), and Venezuelan equine encephalitis virus (VEEV) was found to be safe, well-tolerated and induced a neutralizing antibody response ...
May 12, 2022
0
7
Some therapies successful in treating rheumatoid arthritis (RA) may help us better understand how to treat people with debilitating mosquito-borne viral diseases, new Griffith University research has found.
Mar 8, 2022
1
59
Study results, published today in Nature Biomedical Engineering, show that the novel diagnostic platform has analytical specificity and sensitivity equivalent to a US Centre for Disease Control PCR test for Zika and a diagnostic ...
Mar 7, 2022
0
30
A study conducted at the University of São Paulo (USP) in Brazil suggests people previously infected by Chikungunya virus may develop partial immunity to Mayaro virus. The finding, presented in Journal of Virology, is based ...
Dec 3, 2021
0
2
Dengue, Chikungunya, and Zika viruses have all been recorded in Mexico; however, recent diagnostic advances have improved the accuracy of serological testing. A study publishing December 2nd in PLOS Neglected Tropical Diseases ...
Dec 2, 2021
0
63
Mosquitoes can and do feed on HMBPP-supplemented beetroot juice. This is the findings of a study at Stockholm University. HMBPP is a metabolite which is produced by Malaria parasite, Plasmodium. The researchers have shown ...
Oct 12, 2021
0
22
Alphaviruses—mosquito-borne viruses that can trigger brain infections and arthritis—may have met their match.
Aug 19, 2021
0
144
Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.
Mar 5, 2021
0
2
French-Austrian biotech firm Valneva said Wednesday it will begin clinical trials of its COVID-19 vaccine candidate in Britain, where the government has already ordered at least 60 million doses.
Dec 16, 2020
0
2
